Table 3 Phenotypic analyses of MSC resuspended in three different electrolyte solutions in the presence of 2% (w/v) HSA
From: Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products
Time | Day 0 | Day 1 | Day 2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CD45−/CD105+ | CD31−/CD73+ | HLA-DR− | CD90+ | CD45−/CD105+ | CD31−/CD73+ | HLA-DR+ | CD90+ | CD45−/CD105+ | CD31-/CD73+ | HLA-DR− | CD90+ | |
Plasmalyte 144 | 99.9 | 99.9 | 81.7 | 99.2 | 99.9 | 99.9 | 81.36 | 99.33 | 98.83 | 99.31 | 89.53 | 99.56 |
Ringer | 99.9 | 99.9 | 73.8 | 99.4 | 99.9 | 99.8 | 78 | 98.99 | 99.86 | 99.63 | 86.23 | 99.73 |
Glucoside | 99.8 | 99.8 | 83.5 | 98.7 | 99.8 | 99.8 | 80.1 | 98.68 | 99.82 | 99.79 | 87.51 | 99.54 |